KANSAS CITY, Mo., May 31, 2018 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced the presentation of a scientific poster describing an ongoing first-in-human clinical trial of Ciclopirox Prodrug (CPX-POM), its lead anti-cancer agent, at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting. The ASCO conference, attracting cancer specialists from around the world, is June 1-5, 2018, in Chicago.
Scott J. Weir, Pharm.D., Ph.D., Associate Director – Translational Research at The University of Kansas Cancer Center, will present a poster on the multi-site Phase I trial, entitled “Safety, dose tolerance, pharmacokinetics and pharmacodynamics study of CPX-POM in patients with advanced solid tumors.” Researchers and clinicians can discuss the clinical study with Dr. Weir, a co-inventor of Ciclopirox Prodrug and Acting Chief Scientific Officer of CicloMed, from 8 a.m. to 11:30 a.m. Monday June 4 in Hall A (Abstract No. TPS2618; Poster Board #433a). The abstract is available through ASCO at http://abstracts.asco.org/214/AbstView_214_223195.html.
Authors on the poster include Dr. Weir and colleagues at The University of Kansas Cancer Center; the Principal Investigator in the Phase I study, Howard A. “Skip” Burris III, M.D., Chief Medical Officer and President, Clinical Operations, Sarah Cannon Research Institute; and other members of the CicloMed clinical team.
In addition, a publication-only abstract, “Preclinical development of ciclopirox prodrug for the treatment of non-muscle invasive and muscle invasive bladder cancer” (Abstract No. e14576), is available through ASCO at http://abstracts.asco.org/214/AbstView_214_228365.html.
“We believe Ciclopirox Prodrug holds promise to augment current therapies for bladder cancer with a novel mechanism of action that has potential to inhibit disease progression from non-muscle invasive to muscle-invasive bladder cancer. We are pleased with the opportunity to present CPX-POM data at ASCO 2018, and we look forward to reporting further results in the future,” said Tammy Ham, President and Chief Executive Officer of CicloMed LLC.
Ciclopirox Prodrug was discovered by scientists at The University of Kansas Cancer Center and KU’s Institute for Advancing Medical Innovation (IAMI). CicloMed is developing CPX-POM for the treatment of bladder cancer through a unique public-private partnership with KU Medical Center.
Roy Jensen, M.D., Director of The University of Kansas Cancer Center, said: “Our vision as a National Cancer Institute Cancer Center is to discover and advance promising new cancer treatments to patients. Through our collaboration with CicloMed, Ciclopirox Prodrug has moved from the bench to the clinic, and the ongoing Phase I study has begun to characterize the drug in cancer patients.”
For further information on the first-in-human trial of Ciclopirox Prodrug, please view the study’s disclosure page or search for CicloMed or CPX-POM on www.clinicaltrials.gov.
More than 500,000 men and women are living with bladder cancer in the United States. Bladder cancer is the fifth most common cancer in Americans and the fourth most common cancer in men. According to the American Cancer Society, about 81,000 new cases of bladder cancer will be diagnosed in 2018, and more than 17,000 deaths are expected this year.
About CicloMed LLC
CicloMed is a developmental-stage pharmaceutical company focusing on unmet medical needs in oncology, and Ciclopirox Prodrug is its lead drug candidate. CicloMed is a subsidiary of BioNOVUS Innovations LLC, a Kansas City-based firm committed to investing in individuals and organizations who are transforming healthcare and bringing novel solutions to reality. Portfolio companies have developed new enabling technologies, pharmaceuticals and delivery models that are transformative. For more information, visit www.ciclomed.com.
For further information, contact:
CicloMed media inquiries: Dick Johnson, 913.649.8885, dick@johnsonstrategic.com
CicloMed / BioNOVUS partnering: Tammy Ham, 816.949.8721, info@bionovus.com